Autoimmune pulmonary alveolar proteinosis developed during immunosuppressive treatment in polymyositis with interstitial lung disease: a case report

• Main Authors: S. Sato, K. Akasaka, H. Ohta, Y. Tsukahara, G. Kida, E. Tsumiyama, K. Kusano, T. Oba, T. Nishizawa, R. Kawabe, H. Yamakawa, M. Amano, H. Matsushima, T. Takada
• Format: Article
• Language: English
• Published: BMC 2020-04-01
• Series: BMC Pulmonary Medicine
• Subjects: Pulmonary alveolar proteinosis; Polymyositis; GM-CSF; Immunosuppressive treatment
• Online Access: http://link.springer.com/article/10.1186/s12890-020-1110-5

Abstract Background Pulmonary alveolar proteinosis (PAP) is characterized by the accumulation of surfactant proteins within the alveolar spaces. Autoimmune PAP (APAP) caused by elevated levels of GM-CSF autoantibodies (GM-Ab) is very rarely associated with systemic autoimmune disease. Here we report a case of APAP manifested during immunosuppressive treatment for polymyositis with interstitial lung disease. Case presentation A 52-year-old woman treated at our hospital because of polymyositis with interstitial pneumonia had maintained remission by immunosuppressive treatment for 15 years. She had progressive dyspnea subsequently over several months with her chest CT showing ground-glass opacities (GGO) in bilateral geographic distribution. Her bronchoalveolar lavage fluid with cloudy appearance revealed medium-sized foamy macrophages and PAS-positive amorphous eosinophilic materials by cytological examination. We diagnosed her as APAP due to an increased serum GM-CSF autoantibody level. Attenuating immunosuppression failed to lead GGO improvement, but whole lung lavage (WLL) was effective in her condition. Conclusions PAP should be considered as one of the differential diseases when the newly interstitial shadow was observed during immunosuppressive treatment. WLL should be regarded as the treatment option for APAP concurred in connective tissue disease (CTD).